Neurology Xagena
Disease-modifying therapies ( DMTs ) for multiple sclerosis aim to specifically reduce inflammation in relapsing multiple sclerosis and promote neuroprotection and neurorepair in progressive multiple ...
Results from the TOWER ( Teriflunomide Oral in people With relapsing remitting multiplE scleRosis ) trial that assessed the efficacy and safety of once-daily, oral Teriflunomide ( Aubagio ) in patient ...
Teriflunomide ( Aubagio ) is a once-daily oral immunomodulator approved for the treatment of relapsing-remitting multiple sclerosis. Researchers have assessed the efficacy and safety of Teriflunomi ...
Teriflunomide ( Aubagio ) is an oral disease-modifying therapy approved for treatment of relapsing or relapsing–remitting multiple sclerosis. Researchers aimed to provide further evidence for the sa ...
Multiple sclerosis ( MS ) is a chronic disabling disease of the central nervous system ( CNS ), affecting more than 2 million people worldwide. The disease usually starts in early adulthood, but the ...
TOPIC trial was designed to assess whether early initiation of Teriflunomide ( Aubagio ) in patients who experienced their first neurological symptoms consistent with clinically isolated syndrome ( CI ...
Teriflunomide ( Aubagio ) has a well characterized safety and tolerability profile that is consistent across phase II and III studies in the Teriflunomide clinical development program. Overall, adv ...
New investigational data from a late-stage study has shown that Teriflunomide ( Aubagio ) significantly slows whole brain volume loss ( atrophy ) compared with placebo in patients with a first clinic ...
Positive results for Ofatumumab ( OMB157 ) from the phase III ASCLEPIOS I and II studies were announced. In both head-to-head studies, Ofatumumab has demonstrated superiority over Teriflunomide ( Auba ...
